MS Briefs

Global Burden of Multiple Sclerosis, 1990-2018

Lancet Neurol; 2019 Mar; GBD 2016 Multiple Sclerosis Collaborators


 

The prevalence of multiple sclerosis (MS) has increased substantially in many regions around the world since 1990, according to The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD). These recent findings will be useful for resource allocation and planning in health services. Researchers assessed the epidemiology of MS from 1990 to 2016. Data on prevalence and deaths are summarized in the indicator, disability-adjusted life-years (DALYs), which was calculated as the sum of years of life lost (YLLs) and years of life lived with a disability. They found:

  • In 2016, there were 2,221,188 prevalent cases of MS globally, which corresponded to a 10.4% increase in the age-standardized prevalence since 1990.
  • The highest age-standardized MS prevalence estimates per 100,000 persons were in high-income North America (164.6), western Europe (127.0), and Australasia (91.1), and the lowest were in eastern sub-Saharan Africa (3.3), central sub-Saharan African (2.8), and Oceania (2.0).
  • There were 18,932 deaths due to MS and 1,151,478 DALYs due to MS in 2016.
  • Globally, age-standardized death rates decreased significantly (change −11.5%), whereas the change in age-standardized DALYs was not significant (−4.2%,).

GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269-285. doi:10.1016/S1474-4422(18)30443-5.

Recommended Reading

Integrated analysis suggests cladribine’s safety in MS
ICYMI Multiple Sclerosis
Does rituximab delay disability progression in patients with secondary progressive MS?
ICYMI Multiple Sclerosis
Daclizumab beta may be superior to interferon beta on MS disability progression
ICYMI Multiple Sclerosis
Interferon Beta May Not Affect Pregnancy Outcomes in MS
ICYMI Multiple Sclerosis
Autologous Hematopoietic Stem Cells May Treat Aggressive MS Effectively
ICYMI Multiple Sclerosis
DMTs, stem cell transplants both reduce disease progression in MS
ICYMI Multiple Sclerosis
Examining Pseudobulbar Affect in Multiple Sclerosis
ICYMI Multiple Sclerosis
Body Composition, Disability in People with MS
ICYMI Multiple Sclerosis
Core Temperature Not Elevated at Rest in RRMS
ICYMI Multiple Sclerosis
Interview with Joseph R. Berger, MD, on the Financial Contribution of the MS Specialist
ICYMI Multiple Sclerosis